Neurotech is a medical device and solutions company incorporated in Australia, which operates through its Malta-based subsidiary, AAT Research.

Neurotech is developing neuro-stimulation and neuro-diagnostic solutions to be delivered via the Mente platform, an innovative platform technology to enable medical practitioners to remotely monitor and play an active role in home-based therapies. Neurotech has commercialised its first product, Mente Autism, which assists with the management of children with Autism Spectrum Disorder (ASD) with additional research and development commenced on a number of separate initiatives relating to tinnitus, anxiety, depression and epilepsy.

It is anticipated that NTI will list on the ASX during October 2016.